Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24N6O |
Molecular Weight | 340.4234 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]([H])(C)N=c1[nH]c(C)nc2c(c(C)nn21)-c3ccc(nc3C)OC
InChI
InChIKey=LBWQSAZEYIZZCE-SNVBAGLBSA-N
InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1
Molecular Formula | C18H24N6O |
Molecular Weight | 340.4234 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Pexacerfont is a highly potent and selective CRF1 receptor antagonist that displays no agonist properties. It is specific for CRF1 receptors and has more than 1,000- fold less affinity for CRF2 receptors, and more than 100- fold less affinity for the CRF-binding protein. In extensive preclinical studies, pexacerfont has been shown to inhibit specific binding of CRF to rat, dog, monkey, and human CRF1 receptors. The functional anxiolytic effects of CRF1 receptor occupancy were demonstrated in two rodent models of anxiety, situational anxiety and elevated plus maze paradigms. Pexacerfont did not demonstrate efficacy compared to placebo for the treatment of generalized anxiety disorder in human. The bogus taste tests suggested some protective effect of pexacerfont against eating after a laboratory stressor. Pexacerfont had been in phase II clinical trials for the treatment of irritable bowel syndrome and depression depression.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? | 2009 Jun |
|
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. | 2010 May |
|
In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. | 2012 Jun |
|
Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. | 2013 Apr |
|
Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. | 2013 Mar 1 |
|
A simplified and completely automated workflow for regulated LC-MS/MS bioanalysis using cap-piercing direct sampling and evaporation-free solid phase extraction. | 2013 Mar 15 |
|
Effect of the CRF(1)-receptor antagonist pexacerfont on stress-induced eating and food craving. | 2016 Dec |
|
Medical Therapies in the Pipeline for Irritable Bowel Syndrome. | 2017 Sep |
|
Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. | 2018 Mar |
|
Toxicity of Pexacerfont, a Corticotropin-Releasing Factor Type 1 Receptor Antagonist, in Rats and Dogs. | 2019 Mar/Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20455246
100 mg/day (after a 1 week loading dose of 300 mg/day)
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:07:55 UTC 2021
by
admin
on
Sat Jun 26 09:07:55 UTC 2021
|
Record UNII |
LF1VBG4ZUK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8883
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
LF1VBG4ZUK
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
9884366
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
CHEMBL482950
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
DB12572
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
459856-18-9
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
C542342
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
PEXACERFONT
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
C76508
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY | |||
|
459856-18-9
Created by
admin on Sat Jun 26 09:07:55 UTC 2021 , Edited by admin on Sat Jun 26 09:07:55 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |